Spruce Biosciences
Market cap $116M 2.9M shares (10-Q, Nov 5, 2026) × $40.49 close Nov 17, 2026
Most recent annual filing: 2026-03-09
- TA-ERT tralesinidase alfa BLA filingDec 2026TA-ERT tralesinidase alfa BLA filing, Dec 2026, major
- Avenue Tranche 2 renegotiated corporateJan 1 – Mar 31, 2027Avenue Tranche 2 renegotiated corporate, Jan 1 – Mar 31, 2027, routine
- Adrenyx Biosciences CRHX-101 spin-out corporate1H 2027Adrenyx Biosciences CRHX-101 spin-out corporate, 1H 2027, routine
- Avenue Tranche 3 corporate updateJul–Dec 2027Avenue Tranche 3 corporate update, Jul–Dec 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (2 active programs)
SPR202
CRHX-101 · SPR-202Discontinued (1)
- tildacerfont — Major Depressive Disorder · serious adverse event — significant elevation of liver enzymes in a patient
Capital (as filed)
- Cash
- $87.7M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$13.8M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $87.7M cash, runway second half of 2027 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (5)
- 2026-11-10 UPDATE: Spruce Biosciences (SPRB) - The Factory Held, The Tranche Didn’t ★ Distilled Pro
- 2026-08-24 UPDATE: Spruce Biosciences (SPRB) - The Factory Signed Off 🔒 Paid
- 2026-08-13 UPDATE: Spruce Biosciences (SPRB) - The Patients Just Bought the Stock 🔒 Paid
- 2026-07-28 UPDATE: Spruce Biosciences (SPRB) - They Hired the Man Who Launched Brineura
- 2026-05-08 Spruce Biosciences (SPRB) - Scientific Deep Dive for Tralesinidase and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (5 calls)
Every verdict Biotech Distilled has published on Spruce Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-05-08 Watch Spruce Biosciences (SPRB) - Scientific Deep Dive for Tralesinidase and Pipeline Products Science is sound and capital raises remove near-term bankruptcy risk, but confirmation of successful CMC/PPQ batch manufacturing is needed before initiating a position ahead of the Q4 BLA submission.
- 2026-07-28 Speculative buy speculative UPDATE: Spruce Biosciences (SPRB) - They Hired the Man Who Launched Brineura A 25.8% drawdown on zero news combined with a credible permanent CMO hire (Brineura/NAGLAZYME/VIMIZIM launch veteran) and a 9.1% institutional holder justify a starter speculative position, though PPQ batch confirmation remains outstanding.
- 2026-08-13 Speculative buy speculative UPDATE: Spruce Biosciences (SPRB) - The Patients Just Bought the Stock Advocacy foundations' $5.5M equity purchase, a second Brineura veteran hire, and a funded EAP rehearsal for commercial delivery all corroborate the Q4 BLA timeline, but PPQ batch confirmation remains outstanding so position stays starter-sized.
- 2026-08-24 Buy core UPDATE: Spruce Biosciences (SPRB) - The Factory Signed Off The explicit PPQ batch confirmation condition set in the deep dive is now met — FDA called comparability strategies reasonable, first PPQ batch manufactured, BLA content aligned — justifying an upgrade from speculative starter to core position.
- 2026-11-10 Hold UPDATE: Spruce Biosciences (SPRB) - The Factory Held, The Tranche Didn't Avenue Tranche 2 lapsed undrawn and had to be renegotiated, going-concern language appears in the 10-Q, and dilution before the PDUFA decision now looks likely — downgrading to hold while the regulatory picture (sister MPS surrogate precedent, on-track CMC) remains intact.
- Long call · opened Jul 28, 2026 at $41.60 · -2.7% vs XBI -3.0% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (2 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“We completed the first drug product process performance qualification (“PPQ”) batch in July 2026 and expect to complete the second PPQ batch in December 2026.”
matched to TA-ERT (tralesinidase alfa) · regulatory submission
-
-
-
“Based, in part, on these discussions, we intend to submit the BLA for TA-ERT for the treatment of MPS IIIB in the fourth quarter of 2026, and if successful and FDA approval is received, potentially commercially launch in mid-2027.”
matched to TA-ERT (tralesinidase alfa) · regulatory submission / matched to TA-ERT (tralesinidase alfa) · adcom
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (36)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 9, 2026ReleaseSpruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates→ BD updateSummary on the 8-K
- Nov 9, 2026ReleaseSpruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences→ BD updateSummary on the 8-K
- Nov 9, 20268-KCurrent report: results of operations · EX-99.1→ BD updateWith a December BLA submission weeks away, Spruce just spun out its CAH program into a separate company, flagged a going-concern qualification, and renegotiated its debt — making SPRB a leaner, higher-stakes pure-play on TA-ERT and the FDA's surrogate-endpoint call.
- Nov 9, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 2, 2026ReleaseSpruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
- Oct 15, 2026ReleaseSpruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference
- Oct 8, 2026ReleaseSpruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting
- Sep 8, 2026ReleaseSpruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Aug 26, 2026ReleaseSpruce Biosciences Announces Launch of MPS3BStudy.comBD extracted 1 program update from this document → SPRB pipeline
- Aug 24, 2026ReleaseSpruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026→ BD updateThe factory finally signed off: Spruce confirmed the first PPQ batch manufactured, FDA blessed the CMC comparability strategy post-technology transfer, and the Q4 2026 BLA submission is locked — the single highest-value unknown in this name just became a fact.
- Aug 12, 2026ReleaseCure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
- Aug 12, 2026ReleaseSpruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
- Aug 12, 20268-KCurrent report: results of operations · EX-99.1
- Aug 12, 202610-QQuarterly report
- Aug 3, 2026ReleaseSpruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
- Jul 27, 2026ReleaseSpruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer
- Jul 27, 20268-KCurrent report: officer / director change
- Jul 8, 2026ReleaseSpruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summitvia aggregator
- Jun 29, 2026ReleaseSpruce Biosciences Joins the Russell 3000® Index
- Jun 22, 2026ReleaseSpruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs
- Jun 15, 2026ReleaseSpruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller
- Jun 8, 2026ReleaseSpruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS SymposiumBD extracted 1 program update from this document → SPRB pipeline
- May 28, 2026ReleaseSpruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
- May 27, 2026ReleaseSpruce Biosciences to Participate in Upcoming Conferences in June
- May 26, 20268-KCurrent report: shareholder vote
- May 13, 20268-KCurrent report: results of operations · EX-99.1
- May 13, 202610-QQuarterly report
- Apr 22, 20268-KCurrent report: material agreement, other events · EX-99.1
- Apr 21, 2026424B5Prospectus supplement (offering)
- Apr 20, 2026424B5Prospectus supplement (offering)
- Apr 9, 2026DEFA14AProxy soliciting material
- Apr 9, 2026DEF 14AProxy statement
- Mar 20, 20268-KCurrent report: agreement terminated · EX-99.1
- Mar 9, 20268-KCurrent report: material agreement, agreement terminated, results of operations · EX-99.1
- Mar 9, 2026424B5Prospectus supplement (offering)
- Mar 9, 202610-KAnnual report
17 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 4, 2026SCHEDULE 13G/A13G amendment
- Jul 30, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 27, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 13, 2026S-8Employee plan registration
- May 7, 2026SCHEDULE 13G/A13G amendment
- Apr 28, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 9, 2026ARSAnnual report to shareholders
- Mar 9, 2026S-8Employee plan registration